Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | CCNH | P51946 | 1/20 | 0.50 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.45 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | HTR1F | P30939 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151962 | 0.85 | CDK2 (0.56) | CDK2ALDH1A1CCNT1CDK1CCNB1 | |
| SCHEMBL19736375 | 0.84 | CDK2 (0.49) | CDK2ALDH1A1CCNT1CDK1CCNB1 | |
| SCHEMBL19728689 | 0.83 | CDK2 (0.48) | CDK2ALDH1A1CCNT1CDK1CCNB1 | |
| SCHEMBL28810103 | 0.80 | CDK2 (0.48) | CDK2ALDH1A1CCNT1CDK1CCNB1 | |
| SCHEMBL4511045 | 0.79 | CDK2 (0.53) | CDK2ALDH1A1CCNT1CDK1CCNB1 | |
| SCHEMBL8720225 | 0.78 | CDK2 (0.59) | CDK2ALDH1A1CCNT1CDK1CCNB1 | |
| SCHEMBL5072707 | 0.78 | CDK2 (0.58) | CDK2ALDH1A1CCNT1CDK1CCNB1 | |
| SCHEMBL3421971 | 0.78 | CDK2 (0.58) | CDK2ALDH1A1CCNT1CDK1CCNB1 | |
| SCHEMBL5828213 | 0.78 | CDK2 (0.58) | CDK2ALDH1A1CCNT1CDK1CCNB1 | |
| SCHEMBL4511042 | 0.77 | CDK2 (0.51) | CDK2ALDH1A1CCNT1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107722009-B | Process for producing cyclopropane derivative | 阿拉塔纳医疗股份有限公司 | 2020-12-01 | — | — | CN | disclosed |
| EP-3020712-B1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | ARATANA THERAPEUTICS NV (BE) | 2018-07-04 | — | — | EP | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| EP-3020712-A1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | Aratana Therapeutics NV (BE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2776414-B1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | ARATANA THERAPEUTICS NV (BE) | 2016-03-16 | — | — | EP | disclosed |
| US-9040699-B2 | Method for preparing cyclopropane derivatives | ARATANA THERAPEUTICS NV (BE) | 2015-05-26 | — | — | US | disclosed |
| US-20150051394-A1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | ARATANA THERAPEUTICS NV (BE) | 2015-02-19 | — | — | US | disclosed |
| EP-2776414-A1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | Aratana Therapeutics NV (BE) | 2014-09-17 | — | — | EP | disclosed |
| CN-103930413-A | Process for producing cyclopropane derivative | OKAPI SCIENCES NV | 2014-07-16 | — | — | CN | disclosed |
| WO-2013068042-A1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | OKAPI SCIENCES NV (BE) | 2013-05-16 | — | — | WO | disclosed |
| EP-1816135-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | Ajinomoto Co., Inc. (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | AJINOMOTO CO. INC. (JP) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051394-A1 | METHOD FOR PREPARING CYCLOPROPANE DERIVATIVES | HTR6, P2RY6, HTR1D | CDK2 1245/4885ALDH1A1 780/4885CCNT1 963/4885 |
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | PNP, NUDT1, ADAR | CDK2 2906/4885ALDH1A1 385/4885CCNT1 874/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CDK2 647/4885ALDH1A1 1067/4885CCNT1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.